3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Other solid neoplasm
3
Tumor-Agnostic
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Breast
2
Endocrine
1
Dermatologic
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Neoplasms
1
Neoplasm Metastasis
1
Interventions
fludarabine phosphate
58
Cyclophosphamide
54
Epoetin Alfa
43
Cyclosporine
43
Busulfan
43
Peripheral Blood Stem Cell Transplantation
39
Mycophenolic Acid
34
Darbepoetin alfa
33
Antilymphocyte Serum
31
Whole-Body Irradiation
30
Cytarabine
30
Filgrastim
29
Methotrexate
26
Tacrolimus
25
Radiotherapy
25
Melphalan
24
fludarabine
21
Methylprednisolone
17
Cord Blood Stem Cell Transplantation
17
Etoposide
14
Granulocyte Colony-Stimulating Factor
13
Daunorubicin
13
Rivaroxaban
12
apixaban
11
Thiotepa
11
sargramostim
10
epoetin beta
10
Dalteparin
10
eltrombopag
9
Alemtuzumab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Rosuvastatin Calcium
×
Classical hematology
×
Clear all
NCT01524653
2018-07-10
DISOLVE
University of Vermont
Phase 2
Completed
38 enrolled